Rating Rationale
November 04, 2022 | Mumbai
Saraca Laboratories Limited
Ratings reaffirmed at 'CRISIL BBB/Stable/CRISIL A3+'
 
Rating Action
Total Bank Loan Facilities RatedRs.24.7 Crore
Long Term RatingCRISIL BBB/Stable (Reaffirmed)
Short Term RatingCRISIL A3+ (Reaffirmed)
Note: None of the Directors on CRISIL Ratings Limited’s Board are members of rating committee and thus do not participate in discussion or assignment of any ratings. The Board of Directors also does not discuss any ratings at its meetings.
1 crore = 10 million
Refer to Annexure for Details of Instruments & Bank Facilities

Detailed Rationale

CRISIL Ratings has reaffirmed its 'CRISIL BBB/Stable/CRISIL A3+’ ratings on bank facilities of Saraca Laboratories Limited (Saraca).

  

The ratings continue to reflect Saraca’s established market position as a manufacturer of the active pharmaceutical ingredient for Ranitidine, and its moderate financial risk profile, supported by low leverage. These strengths are partially offset by modest profitability, exposure to regulatory risk, intense competition, and volatile raw material prices.

 

Revenues grew by 19% year on year to Rs 314 crores in fiscal 2022 from Rs. 264 crores in fiscal 2021 primarily led by increased in price realisation of its major product Ranitidine by ~44% even as volumes declined by ~6%. Ranitidine formed ~63% of overall revenue. Revenues from other portfolio of drugs remained flattish at Rs. 115 crore as aginst Rs. 117 crore previous year.v With export opportunities for Ranitidine opening up in new geographies like China, Iran, Bangladesh, Saudi Arabia, Marshall Islands etc., introduction of new products and  scale up of other products in the portfolio, revenue is expected to grow at 5-8% over the medium term.

 

Operating Margins remained negative in fiscal 2022 owing to sharp moderation in gross margins by ~400 bps. Company met ~60% of its raw material requirement from China which saw a drastic increase in prices during the year following COVID related lockdowns and supply chain disruptions. Company has currently changed its procurement policy and dependence on China has come down to ~30% with balance being procured from the domestic market. This coupled with further increase in realizations of Ranitidine and other products and gaining traction in ROW markets is expected to drive margins to ~3.5-5% over the medium term.

 

Saraca’s financial risk profile remained adequate with a strong balance sheet. Healthy net worth of Rs 152 crores with year-end working capital debt of ~Rs 18 crores resulted in strong gearing of 0.12 times. Other debt protection metrics, however, were weak due to operating losses in fiscal 2022. With limited capital spending needs and a expected improvement in business performance, debt metrics are expected to gradually recover over the near to medium term.

Analytical Approach

CRISIL Ratings has taken a standalone view on the business and financial risk profiles of Saraca. 

Key Rating Drivers & Detailed Description

Strengths:

  • Established market position and strong clientele: Saraca is one of the largest producers of Ranitidine in India, accounting for 63% of the turnover in fiscal 2022. Domestic clients include Cadila Pharma, Cadila Healthcare Ltd (‘CRISIL AA+/Positive/CRISIL A1+’ and JB Chemicals (‘CRISIL AA/Stable/CRISIL A1+’). Demand for Ranitidine, however, has been volatile, due to its reduced usage in export markets, which has impacted the company’s revenues, in recent times. The company’s ability to introduce and ramp up sale of new products will hence be critical for sustained revenue growth.

 

  • Moderate financial risk profile: Financial risk profile is moderate, marked by low leverage (0.60 times on March 31, 2022), and supported by adequate net worth of Rs 152 crore. Gearing is expected to remain low in the absence of any major debt funded capex. The company reported minor cash losses in fiscal 2022, but complied with all statutory payments and debt obligations (interest of Rs. 0.69 crore) through efficiently managing its working capital. In fiscal 2023 company is not expected to incur any cash losses but improved traction in ROW markets should result in cash accruals reaching Rs. 8-10 crore from FY2024 onwards. Debt protection metrics too should improve with improvement in cash generation.

 

Weaknesses:

  • Exposure to product concentration risk and adverse change in regulations: Saraca derives around 63% of its revenue from the Ranitidine bulk drug. The top ten customers account for around 30% of the total turnover in fiscal 2022. Any substitution of the product could adversely affect sales, though healthy client relationships partially offset this risk. The company also remains susceptible to regulatory changes in case of further concerns regarding N-Nitrosodimethylamine (NDMA) levels in the product.

 

  • Low profitability; exposure to intense competition and volatile raw material prices: Low capital and technical intensity and easy access to process chemistry skills have attracted several players to the bulk drug manufacturing business. Operating profitability was negative in fiscal 2022 and is susceptible to volatile raw material prices and revenue levels. Besides, operating profitability was also impacted by power shortages in the past, and hence, these factors will remain key monitorables.

Liquidity: Adequate

Liquidity is adequate supported by the absence of any long-term debt obligation and minimal maintenance capex of ~Rs. 1 crore p.a. Fund based Bank limits of Rs 16 crore is utilised to the extent of 50-60% on an average. Improvement in expected cash accrual over next 2 fiscals should suffice to meet modest capex and incremental working capital needs.

Outlook: Stable

CRISIL Ratings believes Saraca’s business risk profile is expected to remain stable in the near to medium term, owing to no adverse regulations with respect to key product Ranitidine in domestic market and higher revenue diversity, contributed from newer products like Pantoprazole and Pregabalin.  Further, the moderate financial risk profile should be sustained through better cash accrual and prudent capex spend.

Rating Sensitivity factors

Upward factors:

  • Significant and sustained scale-up in operations, backed by diversification in product profile, reducing dependence on Ranitidine, and increased exports, leading to cash generation more than Rs.15-18 crores.
  • Sustenance of moderate financial risk profile and low leverage

 

Downward factors:

  • Sustained decline in revenue by over 10-15% per fiscal, because of lower offtake from customers or product substitution and sustenance of low operating margins impacting cash generation
  • Weakening of the financial risk profile because of sharp increase in working capital requirement or debt-funded capex
  • Any adverse regulatory changes further affecting sale of Ranitidine in the domestic or ROW export market

About the Company

Incorporated in 1988 and promoted by Mr Subba Reddy and Mr P S Reddy, Saraca manufactures a single active pharmaceutical ingredient, ranitidine, used in drugs to treat peptic ulcer. The company has two facilities, one each in Hyderabad and Vishakhapatnam. It sells in domestic, as well as global markets (Argentina, Marshall Island, Iran, and Bangladesh).

Key Financial Indicators

Particulars

Unit

2022

2021

Revenue

Rs crore

314

264

Profit after tax (PAT)

Rs crore

-12

-14

PAT margin

%

-4

-5.2

Adjusted debt/adjusted net worth

Times

0.12

0.01

Adjusted interest coverage

Times

-2.56

-3.95

Any other information: Not applicable

Note on complexity levels of the rated instrument:
CRISIL Ratings` complexity levels are assigned to various types of financial instruments and are included (where applicable) in the 'Annexure - Details of Instrument' in this Rating Rationale.

CRISIL Ratings will disclose complexity level for all securities - including those that are yet to be placed - based on available information. The complexity level for instruments may be updated, where required, in the rating rationale published subsequent to the issuance of the instrument when details on such features are available.

For more details on the CRISIL Ratings` complexity levels please visit www.crisilratings.com. Users may also call the Customer Service Helpdesk with queries on specific instruments.

Annexure - Details of Instrument(s)

ISIN

Name of

Instrument

Date of

Allotment

Coupon

Rate (%)

Maturity Date

Issue Size

(Rs crore)

Complexity level

Rating Assigned

with outlook

NA

Cash Credit

NA

NA

NA

9.5

NA

CRISIL BBB/Stable

NA

Letter of Credit

NA

NA

NA

11.5

NA

CRISIL A3+

NA

Standby line of Credit

NA

NA

NA

3.2

NA

CRISIL BBB/Stable

NA

Bank Guarantee

NA

NA

NA

0.5

NA

CRISIL A3+

Annexure - Rating History for last 3 Years
  Current 2022 (History) 2021  2020  2019  Start of 2019
Instrument Type Outstanding Amount Rating Date Rating Date Rating Date Rating Date Rating Rating
Fund Based Facilities LT 12.7 CRISIL BBB/Stable   -- 26-08-21 CRISIL BBB/Stable 13-10-20 CRISIL BBB+/Negative 23-12-19 CRISIL A-/Watch Negative CRISIL A-/Stable
      --   --   -- 24-03-20 CRISIL BBB+/Stable 03-10-19 CRISIL A-/Watch Negative --
      --   --   --   -- 27-02-19 CRISIL A-/Stable --
Non-Fund Based Facilities ST 12.0 CRISIL A3+   -- 26-08-21 CRISIL A3+ 13-10-20 CRISIL A2 23-12-19 CRISIL A2+/Watch Negative CRISIL A2+
      --   --   -- 24-03-20 CRISIL A2 03-10-19 CRISIL A2+/Watch Negative --
      --   --   --   -- 27-02-19 CRISIL A2+ --
All amounts are in Rs.Cr.
Annexure - Details of Bank Lenders & Facilities
Facility Amount (Rs.Crore) Name of Lender Rating
Bank Guarantee 0.5 State Bank of India CRISIL A3+
Cash Credit 9.5 State Bank of India CRISIL BBB/Stable
Letter of Credit 11.5 State Bank of India CRISIL A3+
Standby Line of Credit 3.2 State Bank of India CRISIL BBB/Stable

This Annexure has been updated on 23-Feb-23 in line with the lender-wise facility details as on 09-Feb-23 received from the rated entity.

Criteria Details
Links to related criteria
CRISILs Approach to Financial Ratios
Rating criteria for manufaturing and service sector companies
CRISILs Bank Loan Ratings - process, scale and default recognition
Rating Criteria for the Pharmaceutical Industry
Understanding CRISILs Ratings and Rating Scales

Media Relations
Analytical Contacts
Customer Service Helpdesk

Aveek Datta
Media Relations
CRISIL Limited
M: +91 99204 93912
B: +91 22 3342 3000
AVEEK.DATTA@crisil.com

Prakruti Jani
Media Relations
CRISIL Limited
M: +91 98678 68976
B: +91 22 3342 3000
PRAKRUTI.JANI@crisil.com

Rutuja Gaikwad 
Media Relations
CRISIL Limited
B: +91 22 3342 3000
Rutuja.Gaikwad@ext-crisil.com


Anuj Sethi
Senior Director
CRISIL Ratings Limited
D:+91 44 6656 3100
anuj.sethi@crisil.com


Poonam Upadhyay
Director
CRISIL Ratings Limited
D:+91 22 3342 3386
poonam.upadhyay@crisil.com


Karthick G
Senior Rating Analyst
CRISIL Ratings Limited
B:+91 22 3342 3000
Karthick.G@crisil.com
Timings: 10.00 am to 7.00 pm
Toll free Number:1800 267 1301

For a copy of Rationales / Rating Reports:
CRISILratingdesk@crisil.com
 
For Analytical queries:
ratingsinvestordesk@crisil.com


 

Note for Media:
This rating rationale is transmitted to you for the sole purpose of dissemination through your newspaper/magazine/agency. The rating rationale may be used by you in full or in part without changing the meaning or context thereof but with due credit to CRISIL Ratings. However, CRISIL Ratings alone has the sole right of distribution (whether directly or indirectly) of its rationales for consideration or otherwise through any media including websites and portals.


About CRISIL Ratings Limited (A subsidiary of CRISIL Limited, an S&P Global Company)

CRISIL Ratings pioneered the concept of credit rating in India in 1987. With a tradition of independence, analytical rigour and innovation, we set the standards in the credit rating business. We rate the entire range of debt instruments, such as bank loans, certificates of deposit, commercial paper, non-convertible/convertible/partially convertible bonds and debentures, perpetual bonds, bank hybrid capital instruments, asset-backed and mortgage-backed securities, partial guarantees and other structured debt instruments. We have rated over 33,000 large and mid-scale corporates and financial institutions. We have also instituted several innovations in India in the rating business, including ratings for municipal bonds, partially guaranteed instruments and infrastructure investment trusts (InvITs).
 
CRISIL Ratings Limited ('CRISIL Ratings') is a wholly-owned subsidiary of CRISIL Limited ('CRISIL'). CRISIL Ratings Limited is registered in India as a credit rating agency with the Securities and Exchange Board of India ("SEBI").
 
For more information, visit www.crisilratings.com 

 



About CRISIL Limited

CRISIL is a leading, agile and innovative global analytics company driven by its mission of making markets function better. 

It is India’s foremost provider of ratings, data, research, analytics and solutions with a strong track record of growth, culture of innovation, and global footprint.

It has delivered independent opinions, actionable insights, and efficient solutions to over 100,000 customers through businesses that operate from India, the US, the UK, Argentina, Poland, China, Hong Kong and Singapore.

It is majority owned by S&P Global Inc, a leading provider of transparent and independent ratings, benchmarks, analytics and data to the capital and commodity markets worldwide.

For more information, visit www.crisil.com

Connect with us: TWITTER | LINKEDIN | YOUTUBE | FACEBOOK


CRISIL PRIVACY NOTICE
 
CRISIL respects your privacy. We may use your contact information, such as your name, address and email id to fulfil your request and service your account and to provide you with additional information from CRISIL. For further information on CRISIL's privacy policy please visit www.crisil.com.



DISCLAIMER

This disclaimer is part of and applies to each credit rating report and/or credit rating rationale ('report') that is provided by CRISIL Ratings Limited ('CRISIL Ratings'). To avoid doubt, the term 'report' includes the information, ratings and other content forming part of the report. The report is intended for the jurisdiction of India only. This report does not constitute an offer of services. Without limiting the generality of the foregoing, nothing in the report is to be construed as CRISIL Ratings providing or intending to provide any services in jurisdictions where CRISIL Ratings does not have the necessary licenses and/or registration to carry out its business activities referred to above. Access or use of this report does not create a client relationship between CRISIL Ratings and the user.

We are not aware that any user intends to rely on the report or of the manner in which a user intends to use the report. In preparing our report we have not taken into consideration the objectives or particular needs of any particular user. It is made abundantly clear that the report is not intended to and does not constitute an investment advice. The report is not an offer to sell or an offer to purchase or subscribe for any investment in any securities, instruments, facilities or solicitation of any kind to enter into any deal or transaction with the entity to which the report pertains. The report should not be the sole or primary basis for any investment decision within the meaning of any law or regulation (including the laws and regulations applicable in the US).

Ratings from CRISIL Ratings are statements of opinion as of the date they are expressed and not statements of fact or recommendations to purchase, hold or sell any securities/instruments or to make any investment decisions. Any opinions expressed here are in good faith, are subject to change without notice, and are only current as of the stated date of their issue. CRISIL Ratings assumes no obligation to update its opinions following publication in any form or format although CRISIL Ratings may disseminate its opinions and analysis. The rating contained in the report is not a substitute for the skill, judgment and experience of the user, its management, employees, advisors and/or clients when making investment or other business decisions. The recipients of the report should rely on their own judgment and take their own professional advice before acting on the report in any way. CRISIL Ratings or its associates may have other commercial transactions with the entity to which the report pertains.

Neither CRISIL Ratings nor its affiliates, third-party providers, as well as their directors, officers, shareholders, employees or agents (collectively, 'CRISIL Ratings Parties') guarantee the accuracy, completeness or adequacy of the report, and no CRISIL Ratings Party shall have any liability for any errors, omissions or interruptions therein, regardless of the cause, or for the results obtained from the use of any part of the report. EACH CRISIL RATINGS PARTY DISCLAIMS ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING BUT NOT LIMITED TO ANY WARRANTIES OF MERCHANTABILITY, SUITABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE. In no event shall any CRISIL Ratings Party be liable to any party for any direct, indirect, incidental, exemplary, compensatory, punitive, special or consequential damages, costs, expenses, legal fees or losses (including, without limitation, lost income or lost profits and opportunity costs) in connection with any use of any part of the report even if advised of the possibility of such damages.

CRISIL Ratings may receive compensation for its ratings and certain credit-related analyses, normally from issuers or underwriters of the instruments, facilities, securities or from obligors. Public ratings and analysis by CRISIL Ratings, as are required to be disclosed under the regulations of the Securities and Exchange Board of India (and other applicable regulations, if any), are made available on its website, www.crisilratings.com (free of charge). Reports with more detail and additional information may be available for subscription at a fee - more details about ratings by CRISIL Ratings are available here: www.crisilratings.com.

CRISIL Ratings and its affiliates do not act as a fiduciary. While CRISIL Ratings has obtained information from sources it believes to be reliable, CRISIL Ratings does not perform an audit and undertakes no duty of due diligence or independent verification of any information it receives and/or relies on in its reports. CRISIL Ratings has established policies and procedures to maintain the confidentiality of certain non-public information received in connection with each analytical process. CRISIL Ratings has in place a ratings code of conduct and policies for managing conflict of interest. For details please refer to:
https://www.crisil.com/en/home/our-businesses/ratings/regulatory-disclosures/highlighted-policies.html.

Rating criteria by CRISIL Ratings are generally available without charge to the public on the CRISIL Ratings public website, www.crisilratings.com. For latest rating information on any instrument of any company rated by CRISIL Ratings, you may contact the CRISIL Ratings desk at crisilratingdesk@crisil.com, or at (0091) 1800 267 1301.

This report should not be reproduced or redistributed to any other person or in any form without prior written consent from CRISIL Ratings.

All rights reserved @ CRISIL Ratings Limited. CRISIL Ratings is a wholly owned subsidiary of CRISIL Limited.

 

 

CRISIL Ratings uses the prefix 'PP-MLD' for the ratings of principal-protected market-linked debentures (PPMLD) with effect from November 1, 2011, to comply with the SEBI circular, "Guidelines for Issue and Listing of Structured Products/Market Linked Debentures". The revision in rating symbols for PPMLDs should not be construed as a change in the rating of the subject instrument. For details on CRISIL Ratings' use of 'PP-MLD' please refer to the notes to Rating scale for Debt Instruments and Structured Finance Instruments at the following link: https://www.crisil.com/en/home/our-businesses/ratings/credit-ratings-scale.html